A Randomized, Controlled, Multicenter Phase III Clinical Study of YL201 Versus Investigator's Choice of Chemotherapy in Subjects with Recurrent or Metastatic Nasopharyngeal Carcinoma Who Have Failed Prior PD-(L)1 Inhibitor and At Least Two Lines of Chemotherapy
Latest Information Update: 12 Feb 2025
At a glance
- Drugs YL 201 (Primary) ; Capecitabine; Docetaxel; Gemcitabine
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors MediLink Therapeutics
Most Recent Events
- 10 Feb 2025 Status changed from not yet recruiting to recruiting.
- 09 Oct 2024 Status changed from planning to not yet recruiting.
- 17 Sep 2024 New trial record